Browse studies

Find your next paid study

4 recruiting studies matching your filters

VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate t…

CMV ViremiaHeart Transplant InfectionHeart Transplant Failure and Rejection

Estimated

~$10 – $6,250

Columbia UniversityNCT07079735

Phase 2

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (…

Brain Cancer MetastaticCMV Viremia

Estimated

~$10 – $6,250

The Methodist Hospital Research InstituteNCT07383649

Adaptability of an Undetectable = Untransmissible Model for HBV: Are Suppressed Viral Levels in the Serum Consistent Across Body Fluid Reservoirs?

Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune t…

Chronic Hepatitis bViremia

Estimated

~$10 – $1,125

NYU Langone HealthNCT07449091

Phase 4

Letermovir Versus Valganciclovir for 90 Days in CMV Seropositive Kidney Transplant Recipients: Results of a Single-center Experience.

The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropo…

CMV InfectionCMVCMV Viremia+1 more

Estimated

~$10 – $8,750

Elisabeth KincaideNCT07571135